BioNTech SE
BioNTech SE is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Mainz, DE. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of EUR 2.9 billion and a loss of EUR 1.1 billion (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2836, Biological Products, (No Diagnostic Substances)); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.9 out of ten, 8 of 9 metrics filed and 1 estimated: past 6.7 out of ten, present 5.9 out of ten, future 5.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 8.0 out of ten. No warning events in its filings since 2019. 80th percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 6.4 out of ten. +61.6% a year over 9 filed years; profitable in 4 of 9. 64th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 5.2 out of ten. Share count shrank 1.1% a year. 0% of cash flow returned. Insiders: 27 sales, 0 purchases. 52nd percentile among 21 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 7.5 out of ten. ROE -6%: lost 6¢ per shareholder dollar. Leverage 13%: owes 13¢ per asset dollar. 75th percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 4.1 out of ten. bottom 41% of 102 in its family; net margin -39.6%. 41st percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 130 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
- Room to expand (future): 6.0 out of ten. top 40% of 92 in its family for room to expand. 60th percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 4.4 out of ten. bottom 44% of 100 in its family for growth drivers. 44th percentile among 100 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 4.0 out of ten. bottom 40% of 72 in its family for expectations against reality. 40th percentile among 72 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 20-F filed 2026-03-10 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 4, 2026-10-09. Filings on record since 2019. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: COVID19 Vaccine Revenues 70%, Revenues From Out Licensing 21%, Other Sales 9%. By geography: United States 63%, Germany 27%, Ireland 11%, Rest of the World under 1%. As tagged in its annual report (Form 20-F/A, filed 2026-07-30).
Who runs it
Sahin, Ugur (Chief Executive Officer); Zapata, Gomez Ramon (Chief Financial Officer); Poetting, Sierk (Chief Operating Officer); Hanekamp, Annemarie (Chief Commercial Officer); Jimenez, Kylie (Chief People Officer); Ryan, James Timothy Patrick (Chief Legal Officer and Chief Business Officer); Tureci, Ozlem (Chief Medical Officer); Low-Friedrich, Iris Katharina (director); Schaffert, Susanne (director); Blackwood, Nicola Claire (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-09.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.